IMMU-132 is an anti-TROP2 ADC that has been shown to be effective against various cancers without severe side effects in various cancers [11–18], including metastatic SCLC [14] and NSCLC resistant to anti-PD-1/PD-L1 therapy [15]. This evidence concerns the gene TACSTD2 and small cell lung carcinoma.